A one-year prospective, randomised, placebo-controlled, double-blind, phase II/III safety trial of combination therapy with IFN beta-1a (Avonex®) and mycophenolate mofetil (Cellcept®) in early multiple sclerosis

被引：0
|
作者：
Remington, G. [1 ]
Treadaway, K. [1 ]
Frohman, T. [1 ]
Shah, A. [1 ]
Salter, A. [1 ]
Racke, M. [1 ]
Frohman, E. [1 ]
机构：
[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX USA
来源：
MULTIPLE SCLEROSIS | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S244 / S244
页数：1
相关论文
共 50 条
  • [41] The efficacy and safety of the biosimilar interferon beta-1a Teberif® in patients with relapsing-remitting multiple sclerosis: data from a comparative international multicenter double-blind placebo-controlled randomized phase III study
    Boyko, A.
    Volkova, L.
    Zakharova, M.
    Khabirov, F.
    Kotov, S.
    Parshina, E.
    Patrusheva, O.
    Prokopenko, S.
    Sazonov, D.
    Timchenko, L.
    Chichanovskaya, L.
    Trinitatsky, Y.
    Sherman, M.
    Zinkina-Orikhan, A.
    Tursunova, C.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 863 - 864
  • [42] Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial
    Sorensen, Per Soelberg
    Lycke, Jan
    Eralinna, Juha-Pekka
    Edland, Astrid
    Wu, Xingchen
    Frederiksen, Jette Lautrup
    Oturai, Annette
    Malmestrom, Clas
    Stenager, Egon
    Sellebjerg, Finn
    Sondergaard, Helle Bach
    LANCET NEUROLOGY, 2011, 10 (08): : 691 - 701
  • [43] Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial
    Smolders, Joost
    Hupperts, Raymond
    Barkhof, Frederik
    Grimaldi, Luigi M. E.
    Holmoy, Trygve
    Killestein, Joep
    Rieckmann, Peter
    Schluep, Myriam
    Vieth, Reinhold
    Hostalek, Ulrike
    Ghazi-Visser, Lizette
    Beelke, Manolo
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 311 (1-2) : 44 - 49
  • [44] Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
    Benatar, Michael
    Hansen, Thomas
    Rom, Dror
    Geist, Marie A.
    Blaettler, Thomas
    Camu, William
    Kuzma-Kozakiewicz, Magdalena
    van den Berg, Leonard H.
    Morales, Raul Juntas
    Chio, Adriano
    Andersen, Peter M.
    Pradat, Pierre-Francois
    Lange, Dale
    Van Damme, Philip
    Mora, Gabriele
    Grudniak, Mariusz
    Elliott, Matthew
    Petri, Susanne
    Olney, Nicholas
    Ladha, Shafeeq
    Goyal, Namita A.
    Meyer, Thomas
    Hanna, Michael G.
    Quinn, Colin
    Genge, Angela
    Zinman, Lorne
    Jabari, Duaa
    Shoesmith, Christen
    Ludolph, Albert C.
    Neuwirth, Christoph
    Nations, Sharon
    Shefner, Jeremy M.
    Turner, Martin R.
    Wuu, Joanne
    Bennett, Richard
    Dang, Hoang
    Sundgreen, Claus
    LANCET NEUROLOGY, 2024, 23 (07): : 687 - 699
  • [45] Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial
    Manning, Jessica E.
    Oliveira, Fabiano
    Coutinho-Abreu, Iliano V.
    Herbert, Samantha
    Meneses, Claudio
    Kamhawi, Shaden
    Baus, Holly Ann
    Han, Alison
    Czajkowski, Lindsay
    Rosas, Luz Angela
    Cervantes-Medina, Adriana
    Athota, Rani
    Reed, Susan
    Mateja, Allyson
    Hunsberger, Sally
    James, Emma
    Pleguezuelos, Olga
    Stoloff, Gregory
    Valenzuela, Jesus G.
    Memoli, Matthew J.
    LANCET, 2020, 395 (10242): : 1998 - 2007
  • [46] Efficacy and safety of intramuscular interferon beta-1a in treatment of early onset multiple sclerosis: A 4-year double-blind study
    Pakdoman, H.
    MULTIPLE SCLEROSIS, 2010, 16 (10): : 1273 - 1273
  • [47] Pharmacokinetics and pharmacodynamics of PEGylated interferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized double-blind placebo-controlled study
    Boyko, A.
    Alifirova, V.
    Boyko, O.
    Greshnova, I.
    Zaslavskiy, L.
    Zakharova, M.
    Parshina, E.
    Poverennova, I.
    Sazonov, D.
    Sokolova, I.
    Shur, S.
    Bakhtiyarova, K.
    Dudin, V.
    Khabirov, F.
    Zinkina-Orikhan, A.
    Linkova, Y.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 911 - 911
  • [48] Efficacy and safety of GHX02 in the treatment of acute bronchitis: protocol of a phase II, double-blind, randomised placebo-controlled trial
    Lyu, Yee Ran
    Yang, Won-Kyung
    Park, So Jung
    Kim, Seung-Hyeong
    Kang, Wee-Chang
    Jung, In Chul
    Park, Yang Chun
    BMJ OPEN, 2018, 8 (05):
  • [49] Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
    Rovin, Brad H.
    Teng, Y. K. Onno
    Ginzler, Ellen M.
    Arriens, Cristina
    Caster, Dawn J.
    Romero-Diaz, Juanita
    Gibson, Keisha
    Kaplan, Joshua
    Lisk, Laura
    Navarra, Sandra
    Parikh, Samir V.
    Randhawa, Simrat
    Solomons, Neil
    Huizinga, Robert B.
    LANCET, 2021, 397 (10289): : 2070 - 2080
  • [50] SAFETY AND TOLERABILITY OF SELISISTAT FOR THE TREATMENT OF HUNTINGTON'S DISEASE: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TRIAL
    Reilmann, R.
    Squitieri, F.
    Priller, J.
    Saft, C.
    Mariotti, C.
    Suessmuth, S. D.
    Nemeth, A. H.
    Tabrizi, S. J.
    Quarrell, O.
    Craufurd, D.
    Rickards, H.
    Rosser, A.
    Darpo, B.
    Tessari, M.
    Szynol, A.
    Fischer, D. F.
    Frost, C.
    Farmer, R. E.
    Landwehrmeyer, G. B.
    Westerberg, G.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 : A102 - A102
12345